API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2024/03/27/2853589/0/en/Celcuity-Inc-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Corporate-Update.html
https://www.globenewswire.com//news-release/2024/02/22/2834087/0/en/Celcuity-Announces-First-Patient-Dosed-in-Phase-1b-2-CELC-G-201-Clinical-Trial-of-Gedatolisib-for-the-Treatment-of-Metastatic-Castration-Resistant-Prostate-Cancer.html
https://www.globenewswire.com/news-release/2023/12/06/2791761/0/en/Celcuity-Presents-Preclinical-Data-on-Therapeutic-Effects-of-Gedatolisib-in-Breast-Cancer-Models-at-the-2023-San-Antonio-Breast-Cancer-Symposium.html
https://www.globenewswire.com//news-release/2023/12/01/2789413/0/en/Celcuity-to-Present-Preclinical-Data-for-Gedatolisib-at-the-2023-San-Antonio-Breast-Cancer-Symposium.html
https://www.accesswire.com/731101/Celcuity-Presents-Updated-Results-of-Phase-1b-Study-of-Gedatolisib-in-Patients-with-Advanced-Breast-Cancer-at-the-2022-San-Antonio-Breast-Cancer-Symposium
https://www.accesswire.com/730704/Celcuity-Announces-First-Patient-Dosed-in-Phase-3-VIKTORIA-1-Clinical-Trial-of-Gedatolisib-for-the-Treatment-of-HRHER2-Advanced-Breast-Cancer